<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146782</url>
  </required_header>
  <id_info>
    <org_study_id>10753</org_study_id>
    <nct_id>NCT01146782</nct_id>
  </id_info>
  <brief_title>Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea</brief_title>
  <acronym>ATLAST</acronym>
  <official_title>The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApniCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApniCure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study of the Attune Sleep Apnea System for the treatment of obstructive
      sleep apnea. The objective of the study is to demonstrate safety and effectiveness of the
      Attune Sleep Apnea System to support FDA marketing clearance of the device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of &gt;50% and Treated AHI&lt;20</measure>
    <time_frame>first treatment night</time_frame>
    <description>Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of &gt;50% and treated AHI&lt;20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Last Treatment Night Response (AHI Reduction)</measure>
    <time_frame>At completion of 28 day home use.</time_frame>
    <description>Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in Oxygen Desaturation Index (ODI)</measure>
    <time_frame>First treatment night</time_frame>
    <description>Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">367</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the Attune Sleep Apnea System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Attune Sleep Apnea System</intervention_name>
    <description>Console and mouthpiece sleep apnea system</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is between the ages of 18 and 80.

          2. Diagnosis of OSA, based on ODI 10-60 (as assessed per home screening night).

          3. Subject is fluent in English and understands the Study protocol and is willing and
             able to comply with Study requirements and sign the informed consent form.

          4. BMI &lt; 40.

          5. Subject has a least one molar in each of the four quadrants of the mouth (right upper,
             right lower, left upper, and left lower).

          6. Subject has proper mouthpiece fit, as assessed by home screening night (See section
             8.3).

        Exclusion Criteria:

          1. OSA treatment within two weeks prior to Medical/Dental screening visit.

          2. Poor nasal patency as evidenced by Peak Nasal Inspiratory Flow (PNIF) less than 75
             l/min (assessed at baseline medical visit). In addition, any ongoing process or
             condition that limits nasal breathing or indications thereof, including: obligate
             mouth-breathing, persistent blockage of one or both nostrils resulting in the
             inability to sleep with the mouth closed, chronic nasal congestion, chronic allergic
             rhinitis, and intermittent allergic rhinitis that does not respond to
             non-sedating/non-stimulating medical therapy.

          3. Oral cavity infection or any other oral or dental condition or problem that would
             limit subject use of the Attune Sleep Apnea System (e.g. dentures, loose tooth/teeth,
             temporomandibular joint (TMJ) conditions, or any oral or dental condition that the
             Investigator believes could be exacerbated by the Attune Sleep Apnea System.

          4. Prior use of the Attune Sleep Apnea System.

          5. History of any OSA surgical treatment including uvulopalatopharyngoplasty surgery
             (UPPP), maxillomandibular advancement surgery (MMA), radio frequency (RF) ablation
             treatment, palatal stent devices, etc.

          6. Current use or use within the previous 2 weeks of medications or other agents that may
             affect sleep or PSG, including:

               1. Hypnotics, anxiolytics, anticonvulsants, sedating antihistamines, stimulants,
                  sedating antidepressants or other medications likely to affect neurocognitive
                  function and/or alertness. Patients on stable selective serotonin reuptake
                  inhibitor (SSRI) therapy for &gt; 3 months and who are expected to remain on therapy
                  for the Study duration, may continue SSRI treatment.

               2. Consumption of &gt; 500mg caffeine per day (e.g. &gt; 8 cola-type beverages, &gt; 5 cups
                  of coffee).

               3. Any known illicit drug use or abuse within the past year, or failure to pass drug
                  urine screen test, or alcohol breathalyzer test with result over 0.05% BAL.

               4. Smokers who smoke during the night (interference with PSG).

          7. Any concomitant diagnosed or suspected sleep or chronic neurological disorders, other
             than OSA, including insomnia, and central sleep apnea.

          8. Currently working nights, rotating night shifts, planned travel across four or more
             time zones required during Study period, or within two weeks prior to Study
             enrollment, or sleep schedule not compatible with sleep lab practices.

          9. Potential sleep apnea complications that, in the opinion of the investigator, may
             affect the health or safety of the participant, including: low blood oxygen, recent
             near-miss or prior automobile accident due to sleepiness, reported history of severe
             cardiovascular disease (including NYHA class III or IV heart failure, CAD with angina
             or MI/stroke in past 6 months, uncontrolled hypertension or hypotension, cardiac
             arrhythmias), reported respiratory disorders, or use of medication or other treatment
             which may pose additional risk to the subject or confound the results of the Study.

         10. Female subjects who are pregnant or intend to become pregnant during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Colrain, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Reasearch Institute (SRI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>REM Medical</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Sleep Center</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRI</name>
      <address>
        <city>Menlo Park</city>
        <state>California</state>
        <zip>94025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Center of Georgia (SDCG)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SleepMed</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Associates of Texas (SMAT)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>January 13, 2014</results_first_submitted>
  <results_first_submitted_qc>May 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2014</results_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects for the study were recruited from the Investigatorâ€™s sleep clinic or through advertising. Advertisements were approved by the applicable Institutional Review Board (IRB) prior to use.</recruitment_details>
      <pre_assignment_details>Initial screening phase consisted of initial medical/dental and eligibility screening. Subjects then underwent an Oxygen Desaturation Index (ODI) screening (confirming ODI of 10-60) and one night of home use with the study device to screen for proper fit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sleep Apnea Treatment (Primary Endpoint Cohort)</title>
          <description>The Treatment group (Primary Endpoint Cohort) includes subjects with an evaluable control (without Attune system) and treatment (with Attune system) polysomnogram (PSG).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Screening Cohort</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="221"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Safety Cohort</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Control AHI &lt;5</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>TST &lt;4 hrs</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Primary Endpoint Cohort</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63">63 Subjects in the Primary Endpoint Cohort</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57">57 Subjects in the Primary Endpoint Cohort completed the 28 day study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Demographics and Characteristics are presented for the Safety Cohort</population>
      <group_list>
        <group group_id="B1">
          <title>Safety Cohort</title>
          <description>Demographics and Baseline Characteristics are presented for the Safety Cohort (N=146)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of &gt;50% and Treated AHI&lt;20</title>
        <description>Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of &gt;50% and treated AHI&lt;20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.</description>
        <time_frame>first treatment night</time_frame>
        <population>All subjects in the primary endpoint cohort were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Endpoint Cohort</title>
            <description>The Treatment group (Primary Endpoint Cohort) includes subjects with an evaluable control (without Attune system) and treatment (with Attune system) PSG.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of &gt;50% and Treated AHI&lt;20</title>
          <description>Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of &gt;50% and treated AHI&lt;20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.</description>
          <population>All subjects in the primary endpoint cohort were analyzed.</population>
          <units>subjects with clinical success</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Rate</title>
        <description>Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.</description>
        <time_frame>4 weeks</time_frame>
        <population>The Safety Cohort consisted of all subjects who participated in at-home use of the device.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Cohort</title>
            <description>The Safety Cohort is comprised of all subjects with at least one night of Winx therapy usage.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Rate</title>
          <description>Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.</description>
          <population>The Safety Cohort consisted of all subjects who participated in at-home use of the device.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unanticipated Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device related AEs categorized as mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device related AEs categorized as moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device related AEs categorized as severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Last Treatment Night Response (AHI Reduction)</title>
        <description>Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.</description>
        <time_frame>At completion of 28 day home use.</time_frame>
        <population>All subjects in primary endpoint cohort with final evaluable treatment PSG.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Endpoint Cohort</title>
            <description>The Treatment group (Primary Endpoint Cohort) includes subjects with an evaluable control (without Attune system) and treatment (with Attune system) PSG.</description>
          </group>
        </group_list>
        <measure>
          <title>Last Treatment Night Response (AHI Reduction)</title>
          <description>Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and &gt;30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.</description>
          <population>All subjects in primary endpoint cohort with final evaluable treatment PSG.</population>
          <units>AHI reduction (% change)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.2" lower_limit="-71.7" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction in Oxygen Desaturation Index (ODI)</title>
        <description>Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.</description>
        <time_frame>First treatment night</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary Endpoint Cohort</title>
            <description>The Treatment group (Primary Endpoint Cohort) includes subjects with an evaluable control (without Attune system) and treatment (with Attune system) PSG.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in Oxygen Desaturation Index (ODI)</title>
          <description>Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.</description>
          <units>ODI reduction (% change)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.9" lower_limit="-63.5" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collect at screening, control and treatment PSG, 7 days, 14 days, 21 days, 28 days and after the final treatment PSG.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety Cohort</title>
          <description>Device related adverse events are presented for the Safety Cohort.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Occlusal Change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Dental Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Excessive Salivation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Other Adverse Event</sub_title>
                <description>Other AEs included: blood in mucous/saliva, headache, jaw discomfort, keratosis on tongue, leukoplakia, metallic taste in mouth, nasal congestion, nausea, panic attack.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Oral Tissue Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Oral Tissue Irritation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrea Brown, Director, Clinical Affairs</name_or_title>
      <organization>ApniCure, Inc.</organization>
      <phone>650-361-9000 ext 122</phone>
      <email>abrown@apnicure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

